Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549413 · ClinicalTrials.gov registry record
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
A clinical trial of Esophageal Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT06549413: Recruiting study of Esophageal Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT06549413 is a study of Esophageal Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 2,384-participant average among 17 other Esophageal Carcinoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06549413, a study of Esophageal Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2027-12-31 |
What NCT06549413 shows while recruiting
NCT06549413 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,384-participant average among 17 other Esophageal Carcinoma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Esophageal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06549413 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06549413 about?
NCT06549413 is a clinical study titled "18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer". This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.
What is the current status of trial NCT06549413?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2023-08-23. Estimated completion is 2027-12-31.
What conditions does trial NCT06549413 study?
This clinical trial studies the following conditions: Esophageal Carcinoma.
What interventions are being tested in trial NCT06549413?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06549413?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06549413 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06549413's enrollment target sits among peer trials
60 11th of 17 higher than 7 of 17 other Esophageal Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
RECRUITING · NA
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
RECRUITING · NA
-
National Cancer Institute "Cancer Moonshot Biobank"
RECRUITING
-
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI